| *Sponsored
Breaking News Could Surround (NYSE American: MAIA) With Serious Buzz Thursday July 17th Greetings, Friend!
MAIA Biotechnology, Inc. (NYSE American: MAIA) has breaking news out this Thursday.
After a strong green burst out of the bell, full focus should be considered for this PR:
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
Manuscript featured in leading open-access peer-reviewed scientific journal Nucleic Acids Research
CHICAGO, July 17, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the publication of preclinical data from its second generation ateganosine prodrugs platform in Nucleic Acids Research (NAR), a leading open-access peer-reviewed scientific journal. The study, titled "Novel Telomere-Targeting Dual-Pharmacophore Dinucleotide Prodrugs for Anticancer Therapy," details MAIA’s lead ateganosine (THIO)-derived second-generation prodrugs as promising new molecules in its strategy for enhancing cancer treatment and overcoming drug resistance. The manuscript with the data was published on June 26, 2025, in Volume 53, Issue 12 of the NAR journal.
...
"The reported study data has shown that the sequential combination of MAIA-2022-12 or MAIA-2021-20 with an immune checkpoint inhibitor demonstrated a significantly lower 50% inhibitory concentration with superior anticancer efficacy compared with the corresponding monotherapies. The results suggest that MAIA-2022-12 and MAIA-2021-20 are promising candidates for future preclinical and clinical studies," said MAIA Chairman and CEO Vlad Vitoc, M.D. "We are working now to advance at least one of the candidates into human clinical trials upon completion of required GLP-toxicity and other evaluations."
Read the full article here.
Between this news and a relatively low float of under 26Mn shares, MAIA could earn significant buzz.
Take a quick peek at my initial report below and consider a spot atop your watchlist for (NYSE American: MAIA) when you have a second. -----
This innovative biotech company is gaining attention in the medical field for its unique approach to cancer treatment.
By targeting the fundamental drivers of tumor growth, the company is working to overcome challenges that have limited the success of existing therapies.
Recent clinical results have shown promising progress, and the team behind this work brings strong expertise and a clear dedication to improving patient outcomes.
As the focus on advanced oncology solutions continues to grow, this company is emerging as a standout in the space.
And here’s what adds to the story: this isn’t a new name I'm bringing to you.
First brought up a few months ago, it moved from an alert price of roughly $1.95 to a high of $2.74 in May.
That marks a short-term move of approximately 40%.
Once again consider this breakout idea for your watchlist:
MAIA Biotechnology, Inc. (NYSE American: MAIA)
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.
Their lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. | 
0 Response to "Breaking News Could Surround (NYSE American: MAIA) With Serious Buzz Thursday"
Post a Comment